Anti-VEGF Therapies

Vascular endothelial growth factor (VEGF) contributes to several pathological processes and is therefore a popular target in the research and development of therapies for certain illnesses.

The overexpression of VEGF is a contributing factor to the development of disease. For example, solid tumors require an increased blood supply if they are to continue growing beyond a certain size and tumors that express VEGF are able to do this because VEGF stimulates the formation of new blood vessels, a process referred to as angiogenesis.

Cancers that express VEGF are therefore able to grow and spread (metastasize) to other organs and regions of the body. Expression of this protein has been associated with a poor outcome in breast cancer, with a decreased survival rate observed among individuals with tumors that express VEGF.

VEGF plays a role in the development of diabetic retinopathy and the wet form of age-related macular degeneration. Anit-VEGF therapy is also therefore important in the treatment of these conditions.

Since cancer growth is stimulated by VEGF, researchers have made numerous attempts to decrease its expression and prevent angiogenesis and tumor growth. If the blood supply is reduced, the tumor is literally starved to death. Two of the most well known drugs that have been successful at slowing the progression of disease stimulated by VEGF are monoclonal antibodies bevacizumab (Avastin) and ranibizumab (Lucentis).

Some other examples of anti-VEGF agents include:

  • Lapatinib (Tykerb)
  • Sorafenib (Nexavar)
  • Sunitinib (Sutent)
  • Axitinib
  • Pazopanib

Further Reading

Last Updated: Aug 21, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, August 21). Anti-VEGF Therapies. News-Medical. Retrieved on September 23, 2023 from

  • MLA

    Mandal, Ananya. "Anti-VEGF Therapies". News-Medical. 23 September 2023. <>.

  • Chicago

    Mandal, Ananya. "Anti-VEGF Therapies". News-Medical. (accessed September 23, 2023).

  • Harvard

    Mandal, Ananya. 2023. Anti-VEGF Therapies. News-Medical, viewed 23 September 2023,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Exploring SARS-CoV-2-associated endothelial dysfunction